AstraZeneca reported a stronger-than-expected third quarter, buoyed by demand for its oncology and cardiovascular medicines, though management chose not to lift its full-year forecast.

For the quarter ending September 30, revenue at constant currency reached $15.19 billion, marking a 10% increase year-on-year and topping the $14.79 billion analysts had projected. Adjusted earnings per share climbed 12% to $2.38, ahead of the $2.29 consensus.

The company attributed its momentum to flagship products and is planning new launches — including a blood pressure therapy — to help offset patent expirations such as the diabetes and heart drug Farxiga. U.S. sales, AstraZeneca’s largest market, rose 9% to $6.55 billion, while China contributed $1.76 billion, up 5% despite ongoing regulatory scrutiny.

Despite the encouraging quarterly performance, AstraZeneca kept its full-year guidance unchanged, reiterating expectations for high single-digit revenue growth and low double-digit growth in core earnings. Management pointed to mounting costs and increased generic competition as reasons for maintaining a cautious stance. Core operating expenses expanded 9% to $21.6 billion over the first nine months.

The group is also exploring a U.S. drug pricing agreement and plans a New York Stock Exchange listing to bolster its financial position. Executives say any impact from the proposed pricing deal should be manageable.

Overall, the results underscore AstraZeneca’s capacity to generate strong sales while highlighting the balancing act it faces: advancing launches and financial plans against cost pressures, patent timelines and shifting regulatory landscapes.